A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback